INAB

0.75801.86%
OP

Oxana Polyakova

Senior Vice President of Research & Development

Dr. Oxana Polyakova serves as Senior Vice President of Research & Development at IN8bio, Inc. since September 2026. Dr. Polyakova joined IN8bio from LAVA Therapeutics, a clinical-stage immuno-oncology company developing bispecific ?d T cell engagers, where she served as Chief Scientific Officer. She previously served as Chief Scientific Officer at LIfT Biosciences, a biotechnology company developing a first-in-class neutrophil-based therapy for the treatment of solid tumors. She was Scientific Founder and Head of Discovery at Adaptate Biotherapeutics, a ?d TCE focused spinout of GammaDelta Therapeutics, which was acquired by Takeda. At Adaptate, she designed and led its R&D strategy, established its laboratories and built its R&D team. Prior to Adaptate, Dr. Polyakova served as the Protein and Molecular Leader at GammaDelta Therapeutics. Early in her career, she held scientific and R&D leadership positions at Kesios Therapeutics, Immunocore and GlaxoSmithKline (now GSK). In her new role, Dr. Polyakova helps lead IN8bio’s research and development strategy, with a particular focus on strengthening and accelerating the Company’s T cell engager programs and expanding the potential of its platform across therapeutic areas in autoimmune and oncology. She is Chief Scientific Officer of LAVA Therapeutics N.V. from 2025. Oxana served as chief scientific officer at LIfT BioSciences. She was founding scientist and served as Head of Discovery at Adaptate Biotherapeutics, spin-out of GammaDelta Therapeutics. Over her 20-year career to date, Oxana has worked across multiple therapeutic modalities in both pharma and biotech settings, with significant experience discovering biologics and developing cell therapies for Oncology indications. Oxana holds a Ph.D. from Moscow State University.

Positions